Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
A new orally administered cephalosporin, LB10827, was compared to 16 other antimicrobial agents tested against Streptococcus pneumoniae (520 strains), Haemophilus influenzae (302 strains) and Moraxella catarrhalis (188 strains) by reference broth microdilution methods. LB10827 (MIC90, 0.12 mg/L; highest MIC, 0.5 mg/L) was 8-16-fold more potent than cefdinir, cefpodoxime or cefuroxime when tested against S. pneumoniae. All Gram-negative strains were inhibited at </= 0.5 mg/L LB10827, which is an activity equal or superior to that of currently available and tested oral beta-lactams. LB10827 appears to be a promising agent worthy of continued investigations both in vitro and in vivo.
Deshpande
L M
LM
JMI Laboratories/The JONES Group, 345 Beaver Kreek Center, Suite A, North Liberty, Iowa 52317, USA.
Beach
M L
ML
Mutnick
A H
AH
Jones
R N
RN
D000284:Administration, Oral; D002511:Cephalosporins / Q000494:pharmacology*; D006193:Haemophilus influenzae / Q000187:drug effects*; D001936:Moraxella catarrhalis / Q000187:drug effects*; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D002511:Cephalosporins; C419687:LB 10827